October 2022 in “Journal of experimental and clinical medicine” Repurposing existing drugs for COVID-19 shows promise but requires more research to confirm effectiveness.
1 citations
,
May 2025 in “Frontiers in Veterinary Science” A severe virus outbreak in yaks on the Qinghai-Tibet Plateau caused high death rates and requires targeted control measures.
7 citations
,
March 2023 in “Arabian Journal of Chemistry” Cepharanthine may help treat COVID-19 by targeting multiple pathways.
May 2025 in “Zagazig Journal of Pharmaceutical Sciences/Zagazig Journal of Pharmaceutical Science” Finasteride may help treat Pseudomonas aeruginosa infections by reducing its harmful activities.
January 2022 in “Turkiye Klinikleri Journal of Dermatology” COVID-19 patients with skin signs often stayed in the hospital for less time than those without skin signs.
1 citations
,
January 2023 in “Revista da Associação Médica Brasileira” Experts agree on the need for standardized definitions and education for post-COVID-19 conditions.
5 citations
,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
95 citations
,
August 2022 in “JAMA Network Open” Post-COVID conditions increase health care needs for six months after infection.
2 citations
,
June 2021 in “Медицинский совет” Hair loss from coronavirus can be treated.
December 2024 in “Globus: an international journal of medical science, engineering and technology.”
41 citations
,
February 2021 in “Cureus” Proxalutamide helps COVID-19 patients get rid of the virus faster and recover quicker.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide significantly lowered hospitalization rates in women with mild-to-moderate COVID-19.
45 citations
,
May 1992 in “Journal of Investigative Dermatology” January 2021 in “International Journal of Research in Medical Sciences” During the COVID-19 lockdown, there were fewer cases of mild skin issues and more cases of stress-related skin conditions.
The document concluded that certain compounds might strongly bind to and potentially inhibit a key SARS-CoV-2 protein, but further testing is needed.
4 citations
,
May 2020 in “bioRxiv (Cold Spring Harbor Laboratory)” Migrants from certain regions had a higher risk of COVID-19 than Spaniards.
April 2023 in “Journal of Investigative Dermatology” The COVID-19 pandemic caused a drop in phototherapy for skin conditions, with only 40% of vitiligo and psoriasis patients returning after a hospital closure in Taiwan.
18 citations
,
July 2020 in “Basic and Clinical Andrology” Wait 3 months after COVID-19 before trying assisted reproduction and further research is needed on COVID-19's effects on male hormones and fertility.
5 citations
,
May 2020 in “Dermatologic Therapy” 5-alpha reductase inhibitors might worsen lung recovery in COVID-19 patients, suggesting a pause in their use.
January 2020 in “DOAJ (DOAJ: Directory of Open Access Journals)” The COVID-19 pandemic caused most hair transplant surgeons in India to stop working, and many planned to change their safety measures afterwards.
Collider bias can mislead our understanding of COVID-19 risk and severity.
January 2022 in “Faculty of 1000 Research Ltd” Training programs are needed to improve home COVID-19 management and educate on vital sign monitoring and danger signs.
The extract from the plant Adiantum capillus-veneris might be used to treat COVID-19.
1 citations
,
December 2020 in “Journal of Experimental Biology and Agricultural Sciences” COVID-19 is caused by a virus from bats, and efforts focus on prevention and treatment research.
2 citations
,
July 2020 in “Research Square (Research Square)” Some Moroccan medicinal plants may contain compounds that can inhibit the virus causing COVID-19.
42 citations
,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.
6 citations
,
April 2022 in “Biomedicines” COVID-19 may harm male fertility by affecting sperm production.
29 citations
,
November 2021 in “FEBS Open Bio” Cepharanthine analogues, especially tetrandrine, show potential for treating COVID-19.